Oxygen
NHL
University of RochesterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the NHL cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Isatuximab Indapta Therapeutics, INC. | Phase 2 | B |
Milatuzumab Gilead Sciences | Phase 1/2 | B |
Veltuzumab Gilead Sciences | Phase 1/2 | B |
FALLYPRIDE National Cancer Institute (NCI) | Phase 1/2 | CCC |
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- National Cancer Institute (NCI) | Phase 1/2 | CCC |
View all 32 →
Same molecule, other indications
Oxygen is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →